- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05503342
Monitoring of Patients With Asthma Performed by a Clinical Pharmacist Using a Mobile Application
Pharmacotherapy Follow-up of a Randomized Cohort to Monitor Patients With Asthma on Well-defined Treatment Using a Self-management Mobile Application
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design: interventional study
Patients will be selected according to eligibility criteria and after having agreed and signed an informed consent form, they will be randomized into one of the arms of the study.
At the inclusion visit, demographic data, health history, medication history and allergy history will be collected. They will be evaluated regarding the level of asthma control using the ACQ-6 instrument, as well as the ability to use inhaled medications. They will receive the relevant guidelines regarding the activities that will be carried out during the study.
In both arms, patients will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record weekly three measurements of peak expiratory flow and fill out a questionnaire to assess the control on paper (control group) or fill out a risk score for exacerbation contemplated in the mobile application, which the pharmacist will have access through a web platform (intervention group). Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable.
During the study, a follow-up visit will be carried out and, at the end of the 12 weeks, a closing visit, where will be evaluated the need for medical support during the period, the use of systemic corticosteroids, access to control treatment, the occurrence of adverse event, review of pharmacotherapy and inhalation technique.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
São Paulo, Brazil
- Hospital das Clincias da Faculdade de Medicina da Universidade de São Paulo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Having a diagnosis of asthma and being under medical follow-up for at least six months;
- Meet at least one of the following criteria: a) Have had at least one (01) exacerbation in the last 12 months; b) Have used oral corticosteroids in the last three months; and/or c) Being using high doses of inhaled corticosteroid (budesonide > 800 mcg/day; fluticasone > 500 mcg/day; or beclomethasone > 400 mcg/day - pressurized HFA gas-based device or >1000 mcg/day - other devices).
- Understand, agree and sign the Free and Informed Consent Term.
Exclusion Criteria:
- Illiterate patients or patients with cognitive deficits;
- Patients not fluent in Portuguese;
- Patients without mobile device skills;
- Patients who do not have mobile devices with Android® 6.0 operating system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Control
They will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record three measurements of peak expiratory flow weekly and fill out a questionnaire to assess control on paper. Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable. |
Asthma control assessment questionnaire application in paper format
|
EXPERIMENTAL: Application
They will be followed up in a 12-week pharmacotherapeutic follow-up program, where they will have to record three measurements of peak expiratory flow weekly and fill in an exacerbation risk score included in the cell phone application, which the pharmacist will have access to through a web platform.
Depending on the evolution of each patient, the pharmacist will provide the relevant guidelines to improve control, as well as referral to a medical care service, if applicable.
|
Use of the cell phone application to include information about asthma symptoms which had returned with guidance on self-management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Asthma Control at 4 weeks
Time Frame: 4 weeks after the inclusion visit
|
The evolution of asthma control will be evaluated through repeated measures of a validated control assessment questionnaire (control arm) or by the risk of exacerbation score contemplated in the cell phone application (application arm)
|
4 weeks after the inclusion visit
|
Change in Asthma Control at 12 weeks
Time Frame: 12 weeks after the inclusion visit
|
The evolution of asthma control will be evaluated through repeated measures of a validated control assessment questionnaire (control arm) or by the risk of exacerbation score contemplated in the cell phone application (application arm)
|
12 weeks after the inclusion visit
|
Occurrence of exacerbations
Time Frame: Up to study completion, an average of 12 weeks
|
Assessment of the number of occurrences of severe exacerbations that required medical support.
|
Up to study completion, an average of 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rafael Stelmach, University of Sao Paulo General Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SDC - 4874/19/093
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Asthma control assessment
-
State University of New York at BuffaloNational Center for Advancing Translational Sciences (NCATS)Completed
-
Johns Hopkins UniversityNational Institute of Nursing Research (NINR)Completed
-
UConn HealthAgency for Healthcare Research and Quality (AHRQ)Completed
-
Vanderbilt University Medical CenterAerocrine ABWithdrawn
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); Baltimore City Health Department and other collaboratorsRecruitingAsthma in ChildrenUnited States
-
Arkansas Children's Hospital Research InstituteNational Heart, Lung, and Blood Institute (NHLBI); University of ArkansasCompletedQuality of Life | Asthma | ChildrenUnited States
-
Università degli Studi di FerraraCompletedEffects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients (BIONIGE)Asthma | Asthma; EosinophilicItaly
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Completed
-
University of North Carolina, Chapel HillAmerican Academy of Allergy, Asthma, and ImmunologyCompleted